[Treatment of hepatitis C virus associated extrahepatic manifestations].
Département des Maladies du Foie, Centre Hépato-Biliaire, EPI-99-41, Hôpital Paul-Brousse, 94804 Villejuif.
Jean-Charles
JC
Duclos-Vallée
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D004796:Clinical Enzyme Tests; D002986:Clinical Trials as Topic; D003449:Cryoglobulinemia / Q000209:etiology* / Q000628:therapy; D004359:Drug Therapy, Combination; D015432:Glomerulonephritis, Membranoproliferative / Q000209:etiology* / Q000628:therapy; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000008:administration & dosage / Q000627:therapeutic use; D008010:Lichen Planus / Q000209:etiology*; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology*; D017119:Porphyria Cutanea Tarda / Q000209:etiology*; D011446:Prospective Studies; D011696:Purpura, Thrombocytopenic / Q000209:etiology* / Q000628:therapy; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D012859:Sjogren's Syndrome / Q000209:etiology*; D013959:Thyroid Diseases / Q000209:etiology*; D013997:Time Factors; D000637:Transaminases / Q000097:blood
D000998:Antiviral Agents; D001323:Autoantibodies; D012254:Ribavirin; D007372:Interferons; D000637:Transaminases